10-Q: Capricor Faces FDA Setback, Reports Wider Q2 Loss

Capricor Therapeutics reported a significantly wider net loss in Q2 2025 and received a Complete Response Letter from the FDA for its Duchenne muscular dystrophy therapy, deramiocel, requiring additional clinical data.

Summary

• Capricor Therapeutics reported a net loss of $25.9 million for the three months ended June 30, 2025, a significant increase from $11.0 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $50.3 million, compared to $20.8 million for the six months ended June 30, 2024.
• Revenue for both the three and six months ended June 30, 2025, was $0, down from $4.0 million and $8.9 million respectively in the prior year, as all $50.0 million in U.S. distribution milestone payments from Nippon Shinyaku have been fully recognized.
• Research and development (R&D) expenses increased by 76% to $22.0 million for the three months ended June 30, 2025, and by 74% to $41.0 million for the six months ended June 30, 2025, driven by increased headcount, HOPE-3 clinical trial costs, HOPE-2 OLE trial, and expanded manufacturing efforts.
• General and administrative (G&A) expenses rose by 85% to $5.7 million for the three months ended June 30, 2025, and by 65% to $11.7 million for the six months ended June 30, 2025, primarily due to increased headcount, recruiting costs, and other corporate overhead.
• The company received a Complete Response Letter (CRL) from the FDA in July 2025 for its Biologics License Application (BLA) for deramiocel, citing a lack of substantial evidence of effectiveness and outstanding Chemistry, Manufacturing, and Controls (CMC) items.
• Capricor is preparing a formal written response to the CRL and has scheduled a Type A meeting with the FDA for August 2025, aiming to resubmit its BLA with existing data and potentially supportive HOPE-3 data.
• Topline results from the Phase 3 HOPE-3 clinical trial are expected in the fourth quarter of 2025, with Left Ventricular Ejection Fraction (LVEF) now designated as the primary endpoint.
• Cash, cash equivalents, and marketable securities totaled approximately $122.8 million as of June 30, 2025, down from $151.5 million at December 31, 2024.
• The company estimates its current financial resources are sufficient to fund operations into the fourth quarter of 2026.
• A $3.4 million CIRM grant award was converted into a loan on February 26, 2025, with accrued interest potentially reaching up to $7.1 million.
• Two lawsuits were filed in July and August 2025: a putative securities class action against the company and CEO Linda Marbn, and a derivative action against the Board of Directors, both seeking unspecified damages.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant setback with the FDA's Complete Response Letter for the lead product candidate, deramiocel, which introduces substantial uncertainty and delays to its commercialization. This is compounded by widening net losses and increased operating expenses. While the company has a solid cash position and other promising programs, the immediate regulatory hurdle for its primary value driver is a major concern.

Positives

• Cash, cash equivalents, and marketable securities of approximately $122.8 million as of June 30, 2025, are estimated to fund operations into the fourth quarter of 2026.
• Positive four-year outcomes from the HOPE-2 open label extension (OLE) study demonstrated sustained preservation of cardiac function and a slowing in skeletal muscle decline in Duchenne muscular dystrophy (DMD) patients.
• The FDA accepted the Biologics License Application (BLA) for deramiocel for Priority Review, indicating the potential importance of the therapy.
• The FDA found all responses to the Form 483 observations from the Pre-License Inspection (PLI) of the San Diego manufacturing facility acceptable.
• The Phase 3 HOPE-3 clinical trial has completed its 12-month treatment period, with topline results anticipated in Q4 2025, which could provide confirmatory evidence for deramiocel.
• Deramiocel has received Regenerative Medicine Advanced Therapy (RMAT), orphan drug, and rare pediatric disease designations, making the company eligible for a Priority Review Voucher (PRV) if approved.
• Progress continues on the exosome platform, with the StealthX vaccine entering a NIAID-sponsored Phase 1 clinical trial in August 2025, following IND clearance.

Negatives

• Net loss significantly widened to $25.9 million for Q2 2025 and $50.3 million for the six months ended June 30, 2025, compared to prior periods.
• Zero revenue was recognized for the three and six months ended June 30, 2025, indicating no new milestone achievements or product sales.
• Research and development (R&D) expenses increased substantially by 76% and 74% for the three and six months, respectively, contributing to higher operating losses.
• General and administrative (G&A) expenses also increased significantly by 85% and 65% for the three and six months, respectively, adding to the operational burn.
• The FDA issued a Complete Response Letter (CRL) for the deramiocel BLA, stating it does not meet the statutory requirement for substantial evidence of effectiveness and requires additional clinical data, which will delay potential approval.
• The CRL also cited outstanding Chemistry, Manufacturing, and Controls (CMC) items, despite some having been previously addressed.
• Two lawsuits were filed in July and August 2025: a putative securities class action and a derivative action, which will incur costs and divert management attention.

Risks

• The company will require substantial additional capital to fund operations, and there is no assurance that financing will be available on favorable terms or at all.
• Failure to obtain additional financing could lead to delays, curtailment, or termination of clinical trials and research and development programs.
• Existing stockholders may experience substantial dilution if additional equity securities are issued.
• The success of deramiocel and other product candidates depends on successful development, regulatory approval, and commercialization, which are lengthy and expensive processes.
• The duration and cost of clinical trials are uncertain and can vary significantly due to unanticipated events, patient recruitment rates, manufacturing costs, and regulatory requirements.
• The company is subject to legal proceedings, including a securities class action and a derivative action, which are costly, time-consuming, and could harm the business and stock price.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it seeks to develop and commercialize deramiocel and its exosome platform. Substantial additional funding will be required to support continuing operations, which may come from equity or debt financings, licensing, or strategic collaborations. The company does not expect to complete product development for several years, if ever, and will not generate commercial product revenue until regulatory approvals are secured. Topline results from the Phase 3 HOPE-3 clinical trial are anticipated in the fourth quarter of 2025, which may support a resubmission of the BLA for deramiocel.

Management Comments

• We are actively preparing a formal written response to the Complete Response Letter (CRL) and have scheduled a Type A meeting with the FDA for August 2025.
• Pending regulatory guidance, we seek to resubmit our BLA based on our existing dataset and with HOPE-3 data potentially serving as supportive and confirmatory evidence.
• We have internally addressed the remaining CMC issues noted in the CRL and have prepared formal responses which we plan to submit with our response to the CRL.
• We amended the HOPE-3 study protocol to designate LVEF as the primary endpoint, shifting the focus to cardiac efficacy, reflecting the FDA's emphasis on well-controlled cardiac outcome measures in DMD.
• We aim to efficiently scale commercial efforts in key markets upon potential approval of deramiocel.
• Our strategy for the exosome platform is to identify partners who can provide capital and development expertise to support clinical advancement across targeted indications.

Industry Context

Capricor Therapeutics operates in the highly competitive and challenging clinical-stage biotechnology sector, specifically targeting rare diseases like Duchenne muscular dystrophy (DMD) and developing novel exosome-based therapeutics. The DMD therapeutic landscape includes dystrophin-restoring approaches like exon-skipping and gene therapy, which deramiocel differentiates from by focusing on immunomodulatory, anti-inflammatory, pro-angiogenic, and anti-fibrotic mechanisms. The exosome platform represents an emerging class of cell-free therapeutic agents with potential applications across infectious diseases and monogenic disorders, offering advantages in storage and handling compared to traditional biologics. The FDA's stringent regulatory environment, as evidenced by the Complete Response Letter, underscores the high bar for approval in this space.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. However, the company's focus on Duchenne muscular dystrophy (DMD) places it in a competitive landscape with other companies developing therapies for this rare genetic disorder, including those pursuing gene therapy and exon-skipping approaches.
• The FDA's Complete Response Letter (CRL) for deramiocel indicates that the current data package did not meet the agency's 'substantial evidence of effectiveness' standard, which is a common challenge in drug development, particularly for novel therapies in rare diseases where clinical endpoints can be complex.
• The company's cash runway into Q4 2026, while positive, is typical for clinical-stage biotechs that rely on external financing to fund extensive R&D and clinical trial costs prior to commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• On July 17, 2025, a putative securities class action was filed in the Southern District of California, naming Capricor Therapeutics, Inc. and CEO Linda Marbn, alleging violations of U.S. federal securities laws and seeking unspecified damages.
• On August 1, 2025, a derivative action was filed in the Southern District of California naming each of the Directors on the Board of Capricor Therapeutics, Inc., alleging breaches of fiduciary duties and seeking unspecified damages.

Related Party Transactions

• Consulting Agreement with Dr. Frank Litvack (Executive Chairman and Board Member) for $10,000 per month for consulting services.
• Consulting Agreement with Michael Kelliher (Board Member) for business development services, including an option to purchase 30,000 shares of common stock.
• Commercialization and Distribution Agreements with Nippon Shinyaku (a more than 10% shareholder) for deramiocel in the United States and Japan, involving upfront payments, milestone payments, and product revenue sharing.
• Binding Term Sheet with Nippon Shinyaku for commercialization and distribution of deramiocel in the European region, with potential upfront and milestone payments.
• Private Placement of 2,798,507 shares of common stock to Nippon Shinyaku for approximately $15.0 million in September 2024.

Stakeholder Impact

• Shareholders: Face potential significant dilution from future capital raises, increased stock price volatility due to regulatory setbacks and legal proceedings, and a delay in potential commercial revenue from deramiocel.
• Employees: Increased headcount and compensation expenses indicate growth in the workforce, but the company's financial losses and regulatory challenges could create uncertainty.
• Patients (DMD): The delay in deramiocel's FDA approval means a longer wait for a potentially transformative therapy for Duchenne muscular dystrophy-associated cardiomyopathy, which currently has no approved specific treatments.
• Partners (Nippon Shinyaku): The FDA's CRL impacts the timeline and certainty of deramiocel's commercialization in the U.S., affecting their distribution plans and potential milestone payments.
• Creditors (CIRM): The conversion of the CIRM grant to a loan means the company now has a direct liability, with potential accrued interest of up to $7.1 million, impacting future cash flows.

Next Steps

• Prepare and submit a formal written response to the FDA's Complete Response Letter (CRL) for deramiocel.
• Attend a Type A meeting with the FDA in August 2025 to discuss the path forward for deramiocel's BLA.
• Report topline results from the Phase 3 HOPE-3 clinical trial in the fourth quarter of 2025.
• Potentially resubmit the BLA for deramiocel based on existing data and with HOPE-3 data serving as supportive evidence.
• Initiate discussions with health authorities in Europe and Japan to define potential approval pathways for deramiocel.
• Advance the exosome platform, including the NIAID-sponsored Phase 1 clinical trial of the StealthX vaccine, which initiated in August 2025.
• Identify partners for the exosome platform to support clinical advancement.
• Continue negotiations with Nippon Shinyaku for a definitive commercialization and distribution agreement for deramiocel in the European region, with the term sheet extended to September 30, 2025.

Key Dates

Recommendation

The FDA's Complete Response Letter (CRL) for deramiocel's Biologics License Application (BLA) is a significant negative catalyst, indicating a substantial delay and increased uncertainty for the company's lead product candidate. This regulatory setback, combined with widening net losses and increased cash burn, fundamentally alters the near-term investment thesis. While the company has a solid cash position and other pipeline assets, the primary value driver has hit a major roadblock, increasing the risk profile significantly. Investors should consider reducing exposure given the immediate negative news and the prolonged path to potential commercialization.

Keywords

Biotechnology, Duchenne Muscular Dystrophy, DMD, Deramiocel, CAP-1002, Exosomes, Cell Therapy, FDA, BLA, Clinical Trials, Rare Disease, Orphan Drug, Nasdaq, SEC Filing, Quarterly Report